Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 11, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 1,550,000 ordinary shares.
- Repurchase Price: 1,321.4518 pence per share.
- Treasury Shares Held: 388,772,158 shares (representing 6.90% of total voting rights).
- Shares in Issue: 5,634,135,434 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the increase in the company's Treasury share holdings following the open market purchase on September 11, 2007. The total number of shares held in Treasury now represents 6.90% of the total voting rights in the Company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Points
- Verify the total number of shares in issue (5,634,135,434) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (388,772,158) and its percentage of voting rights (6.90%).
- Note that this filing does not contain financial results; refer to Form 20-F for comprehensive financial data.